Premium
Lack of effect of rheumatoid arthritis on clonixin metabolism
Author(s) -
Furst Daniel E.,
Paulus Harold E.
Publication year - 1975
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1975175622
Subject(s) - rheumatoid arthritis , medicine , globulin , gastroenterology , albumin , arthritis
The effect of rheumatoid arthritis on the metabolism of the analgesic, 2‐(3‐chloro‐o‐toluidino) nicotinic acid (clonixin), was evaluated in 12 patients with rheumatoid arthritis and in 12 matched healthy control subjects. Males, age‐matched by decades, had no renal, gastrointestinal, or hepatic disease, and took no drugs during the study. Lower (p < 0.02) serum albumins and higher globulins in the patients (albumin: 3.87 ± 0.18; globulin: 3.14 ‐ 0.28 gm/100 ml) than in the control subjects (albumin: 4.42 ± 0.10; globulin: 2.36 ± 0.08 gm/l00 ml) were considered to be manifestations of rheumatoid arthritis. Fasting subjects were given single oral doses of 750 mg of clonixin. A spectrophotometric method was used to determine drug blood levels. Serum half‐life was 1.45 ± 0.12 hr inpatients and 1.50 ± 0.13 hr in control subjects (p > 0.5). Mean peak concentration developed at 1.7 hr and was 40.0 ± 2.6 μg/ml for patients and 46.1 ± 3.1 μg/ml for control subjects. Thus a single oral dose of clonixin results in comparable blood levels in male patients suffering from rheumatoid arthritis and in healthy control subjects.